HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Laurent Greillier Selected Research

Immunotherapy

4/2024Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study.
11/2023Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.
6/2023Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.
1/2023First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
12/2021Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data.
10/2020[Predictable toxicities with futures immunotherapies or combinations].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Laurent Greillier Research Topics

Disease

46Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2024 - 04/2004
42Neoplasms (Cancer)
05/2024 - 01/2008
15Malignant Mesothelioma
01/2022 - 11/2007
13Lung Neoplasms (Lung Cancer)
05/2024 - 03/2012
11Mesothelioma
02/2024 - 01/2008
7Small Cell Lung Carcinoma (Small Cell Lung Cancer)
04/2024 - 11/2017
6Brain Neoplasms (Brain Tumor)
03/2024 - 11/2017
6Neoplasm Metastasis (Metastasis)
11/2023 - 11/2010
3Disease Progression
01/2023 - 12/2018
3Thymoma (Thymic Carcinoma)
01/2022 - 01/2016
3Neutropenia
01/2020 - 11/2017
2Frailty
12/2021 - 12/2020
2Adenocarcinoma
11/2021 - 12/2014
2Encephalitis (Encephalitis, Rasmussen)
01/2021 - 01/2019
2Carcinoma (Carcinomatosis)
01/2021 - 11/2018
2Febrile Neutropenia
01/2020 - 11/2017
2Asthenia
01/2020 - 01/2019
2Fatigue
01/2019 - 06/2017
2Pleural Effusion (Pleural Effusions)
04/2016 - 01/2008
1Autoimmune Diseases (Autoimmune Disease)
04/2024
1Interstitial Lung Diseases (Interstitial Lung Disease)
04/2024
1Microsatellite Instability
02/2024
1Weight Loss (Weight Reduction)
05/2023
1Oncogene Addiction
01/2023
1Neuralgia (Stump Neuralgia)
01/2023
1Cognitive Dysfunction
05/2022
1COVID-19
01/2022
1Malnutrition (Nutritional Deficiencies)
12/2021
1Edema (Dropsy)
01/2021
1Pneumonia (Pneumonitis)
01/2021
1Heart Failure
01/2021
1Thrombocytopenia (Thrombopenia)
01/2020
1Sepsis (Septicemia)
01/2020
1Peripheral Nervous System Diseases (PNS Diseases)
10/2019
1Massive Hepatic Necrosis
01/2019
1Adenocarcinoma of Lung
01/2019

Drug/Important Bio-Agent (IBA)

16Pemetrexed (MTA)FDA Link
11/2023 - 03/2009
10Cisplatin (Platino)FDA LinkGeneric
11/2023 - 04/2011
9Immune Checkpoint InhibitorsIBA
05/2024 - 12/2018
9Bevacizumab (Avastin)FDA Link
01/2023 - 04/2016
8PlatinumIBA
05/2024 - 01/2019
8pembrolizumabIBA
03/2024 - 11/2019
8Biomarkers (Surrogate Marker)IBA
02/2024 - 01/2008
5Carboplatin (JM8)FDA LinkGeneric
11/2023 - 01/2020
5LigandsIBA
10/2023 - 01/2019
5IpilimumabIBA
01/2022 - 03/2012
5NivolumabIBA
01/2022 - 01/2019
4B7-H1 AntigenIBA
05/2024 - 01/2019
4atezolizumabIBA
11/2023 - 01/2019
4AsbestosIBA
04/2016 - 01/2008
3Adrenal Cortex Hormones (Corticosteroids)IBA
04/2024 - 10/2023
3Vinorelbine (Navelbine)FDA LinkGeneric
01/2022 - 07/2017
2Proteins (Proteins, Gene)FDA Link
05/2024 - 01/2019
2Immunoconjugates (Immunoconjugate)IBA
05/2024 - 01/2020
2Gefitinib (Iressa)FDA Link
02/2024 - 06/2005
2osimertinibIBA
02/2024 - 01/2019
2ErbB Receptors (EGF Receptor)IBA
01/2024 - 01/2023
2Tyrosine Kinase InhibitorsIBA
01/2023 - 02/2018
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2023 - 04/2016
2Docetaxel (Taxotere)FDA Link
01/2022 - 11/2021
22- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA
12/2021 - 12/2020
2nintedanibIBA
11/2021 - 11/2017
2Circulating Tumor DNAIBA
01/2021 - 11/2020
2Topotecan (Hycamtin)FDA LinkGeneric
01/2021 - 01/2020
2Surface Antigens (Surface Antigen)IBA
01/2020 - 01/2008
2Sunitinib (Sutent)FDA Link
11/2016 - 01/2016
1ParaffinIBA
02/2024
1Formaldehyde (Formol)FDA Link
02/2024
1Anti-Bacterial Agents (Antibiotics)IBA
10/2023
1AntibodiesIBA
06/2023
1Analgesics (Analgesic Drugs)IBA
01/2023
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2023
1Cell-Free Nucleic AcidsIBA
10/2022
1AmphiregulinIBA
01/2022
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2022
1VaccinesIBA
01/2022
1Trastuzumab (Herceptin)FDA Link
01/2022
1pertuzumabIBA
01/2022
1lenvatinibIBA
01/2022
1Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric
12/2020
1C-Reactive ProteinIBA
12/2020
1Antineoplastic Agents (Antineoplastics)IBA
01/2020
1Etoposide (VP 16)FDA LinkGeneric
01/2020
1rovalpituzumab tesirineIBA
12/2019
1lorlatinibIBA
12/2019
1trametinibIBA
01/2019
1alectinibIBA
01/2019
1Anaplastic Lymphoma KinaseIBA
01/2019

Therapy/Procedure

27Therapeutics
05/2024 - 11/2007
27Drug Therapy (Chemotherapy)
05/2024 - 11/2007
6Immunotherapy
04/2024 - 10/2020
5Radiotherapy
01/2021 - 11/2007
3Combination Drug Therapy (Combination Chemotherapy)
10/2023 - 01/2020
2Chemoradiotherapy
01/2024 - 04/2018
2Activities of Daily Living (ADL)
05/2022 - 01/2022
2Precision Medicine
01/2021 - 12/2017
1Home Nursing (Nursing, Home)
07/2021
1Cryosurgery
01/2021
1Ambulatory Care (Outpatient Care)
12/2020
1Medication Reconciliation
01/2020